FAQ: Aditxt Inc. Subsidiary Pearsanta's Clinical Study for Blood-Based Endometriosis Test
Summary
Aditxt Inc.'s subsidiary Pearsanta has begun enrollment in a clinical study for the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. This study aims to validate a non-invasive alternative to laparoscopic surgery, potentially enabling earlier and more accurate diagnosis of the condition.
What is the main announcement in this content?
Aditxt Inc.’s subsidiary Pearsanta has initiated enrollment in a clinical study for the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis.
What is the Mitomic Endometriosis Test (MET)?
MET is a novel blood-based diagnostic test designed for early detection of endometriosis, offering a non-invasive alternative to current diagnostic methods.
Why is this clinical study significant?
The study aims to validate a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis compared to the current gold standard of laparoscopic surgery.
How will the MET test be evaluated in the study?
The study will compare MET’s performance to laparoscopic diagnosis, which is the current gold standard for endometriosis detection, across up to 1,000 participants referred for surgery.
Where has enrollment for the clinical study begun?
The first enrollment site is Dedicated to Women OB/GYN in Dover, Delaware.
Who is leading this initiative for Pearsanta?
Pearsanta President Chris Mitton stated that this milestone supports validation of a non-invasive diagnostic alternative for endometriosis.
What is Aditxt Inc. and what does the company do?
Aditxt Inc. is a social innovation platform that accelerates promising health innovations through an ecosystem of research institutions, industry partners, and shareholders, with programs focused on autoimmunity, cancer and early disease detection, infectious diseases, and women’s health.
Where can investors find more information about Aditxt Inc.?
The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX.
What makes Aditxt’s innovation platform unique?
Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress through multiple disciplines driving disruptive growth.
How does the current diagnostic method for endometriosis compare to the new test?
The current gold standard for endometriosis diagnosis is laparoscopic surgery, while the MET test being studied is a non-invasive blood-based diagnostic that could provide earlier detection without surgical intervention.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 265882